Tarsus Pharmaceuticals Profit Margin

The latest profit margin for TARS is -7.67% as of June 2026. That compares with -31.13% in the prior-year period — up 75.4% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Tarsus Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, TARS's profit margin moved from -31.13% to -7.67% — a 75.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Tarsus Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, TARS currently prints -7.67% for profit margin, while the sector average sits near 13.89%. That is roughly 155.2% below the sector mean. Large gaps often invite a closer look at Tarsus Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Tarsus Pharmaceuticals converts resources into returns. At -7.67%, TARS may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -31.13% in the prior-year period — up 75.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TARS's profit margin (-7.67%), review year-over-year change from -31.13%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.